【Latest Breakthrough】Brand New Treatment for NSCLC Brings Hope

The article discusses the challenges and current treatment methods for non-small cell lung cancer (NSCLC), which remains a leading cause of cancer-related deaths globally. Traditional approaches like chemotherapy, radiotherapy, and surgery have limitations, prompting the exploration of innovative treatments. A breakthrough is presented with the AEGEAN study, a phase III clinical trial evaluating the efficacy and safety of Duvalizumab in a "neoadjuvant immunotherapy + surgical resection + postoperative adjuvant immunotherapy" regimen for resectable NSCLC patients. The study's results indicate significant improvements in pathologic complete response (pCR) and event-free survival (EFS), supporting the effectiveness of the neoadjuvant immunotherapy approach. The article emphasizes the hope for continued advancements in treatment strategies and the inclusion of PD-L1 in the array of tumor treatment drugs.